Clinical Trials Browser

Urinary Bladder Neoplasms, Gallbladder Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Skin Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms

NCT05722886 2025-11-24

DETERMINE

Phase 2/3 Recruiting

825 enrolled

LymphoidOther hematologic neoplasm

Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Hematologic Neoplasms

NCT04759248 2025-09-09

ATREZZO

Phase 2 Active not recruiting

55 enrolled

Breast

Breast Neoplasms, Neoplasms

NCT04341181 2025-07-25

ProTarget

Phase 2 Recruiting

300 enrolled

Tumor-Agnostic

Neoplasms

NCT06031233 2025-05-21

MINUTE

Phase 4 Recruiting

679 enrolled

Tumor-Agnostic

Neoplasms

NCT06589830 2025-05-15

TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer

Phase 2 Not yet recruiting

80 enrolled

Gastrointestinal

Neoplasms, Colorectal Neoplasms

Clinical Trials

TAPUR

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

I-SPY

H3RAKLES

Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer

DETERMINE

DETERMINE

ATREZZO

ProTarget

MINUTE

TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer